Hospital Costs for Patients with Lower Extremity
Background. Hospital admissions for non-purulent lower extremity cellulitis (NLEC) are common and can be prolonged and costly. Newer treatment options and prophylactic strategies should be expected to result in cost savings before implementation, but few studies have quantified the cost of conventional treatment.
Methods. Using the Rochester Epidemiology Project, the incidence of NLEC in Olmsted County, MN in 2013 was 176.6 per 100,000 persons. The subset of patients who required hospitalization for NLEC was determined. Hospital admissions were analyzed retrospectively using standardized cost analysis within several relevant categories.
Results. Thirty-four patients had an average hospital length of stay of 4.7 days. The median total inpatient cost was $7,341. The median cost per day was $2,087. The bulk of this cost was related to room and board. Antibiotics for treatment of NLEC contributed a median cost of $75 per day of hospitalization, and laboratory or imaging tests cost $73 and $44, respectively, per day of hospitalization.
Conclusion. Hospitalizations NLEC can be costly and prolonged, although antibiotic therapy was relatively inexpensive as compared with room and board. Therefore, newer treatment strategies should aim to reduce hospital length of stay and/or avoid inpatient admission to reduce cost.
Disclosures. Background. Abscesses are a common health issue for people who inject drugs (PWID). Females have a higher risk of abscesses, yet it is unclear if the risks are comparable among female sub-populations. The goal of this study was to examine the associations between gender, sex work, and risks of abscesses in PWID.
Methods. We combined data from two cross-sectional studies conducted in the greater Boston area with 225 participants aged 18-45 years, who participated in injection drugs use in the previous 30 days. Demographics, injection-mediated risks, and sexual behaviors were collected using ACASI. Injection drug use was defined as "high" if injection frequencies exceeded the median. Odds ratios from multivariable logistic regressions were used to represent the associations; all analyses were gender-stratified.
Results. The cohort was 31% women (71/225). White race was more common in women than men (89% vs. 63%). Women were more likely than men to report: sex work 31% vs. 14%, heavy heroin use 56% vs. 40%, HCV 76% vs. 61%, abscesses 54% vs. 38%. Controlling for confounders, females who engaged in sex work had >7 times higher odds of reporting abscesses [AOR 7.51; 95% CI (1.41, 40.07)]. There was no association between sex work in men and increased risk for abscess.
Conclusion. We found a gender-specific association between sex work, injection drug use, and abscesses among PWID. The cross-sectional designs precluded causal inferences; further longitudinal studies are necessary to better understand the gender-associated risks for abscesses and to develop harm reduction interventions.
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Background.
Dalbavancin is a lipoglycopeptide with activity against Grampositive pathogens responsible for ABSSSI, including methicillin-resistant Staphylococcus aureus (MRSA), and is FDA-approved as a single-or two-dose regimen. The objective of this study was to assess efficacy and safety of dalbavancin for the treatment of ABSSSI among overweight and obese patients.
Methods. This was a subanalysis of a previously published randomized, double-blind, phase 3 trial of 698 patients with ABSSSI, defined as major abscess, cellulitis, or traumatic wound/surgical site infection and an area of erythema ≥75 cm 2 . Patients were randomized 1:1 to receive dalbavancin 1500 mg intravenously (IV) as a single dose or as two doses: 1000 mg on Day 1 and 500 mg on Day 8. The primary outcome measure was clinical response at 48-72 hours, defined as ≥20% reduction in infection-associated erythema. Clinical success (resolution or improvement in all signs and symptoms; no further antibiotic treatment needed) was assessed at Days 14 and 28. Safety was assessed at every visit.
Results. There were 237 patients with normal weight (BMI <25), 221 patients who were overweight (BMI 25 to <30), and 240 patients who were obese (119 with BMI 30 to <35; 60 with BMI 35 to <40; 61 with BMI ≥40). Rates of diabetes, hypertension, SIRS, and cellulitis were higher in obese patients (Figure 1 ). Clinical success rates at end-of-treatment visit and final visit were similar between normal weight, overweight, or obese patient groups (Figure 2 ). Study drug-related treatment-emergent adverse events (TEAEs) were observed in 7.2% of normal weight patients, 4.6% of overweight patients, and as follows in obese patients: 7.6% (BMI 30 to <35), 11.7% (BMI 35 to <40), and 13.1% (BMI ≥ 40 kg/m 2 ). Rates of serious TEAEs were similar between groups, ranging from 0 to 3.3% among BMI groups. Rates of TEAEs were also similar to those reported for dalbavancin in previous phase 3 trials.
Conclusion. Dalbavancin is effective and well tolerated in overweight and obese patients. A recent French study using IV ertapenem for ≥4 weeks showed significant control of severe HS in patients (patients) who failed alternate medical strategies. We performed a prospective trial to study the effectiveness of IV ertapenem in severe HS.
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Methods. A prospective pilot clinical study was done at Henry Ford Hospital, Detroit from May 2013 to December 2015. All patients with severe HS (Hurley Stage III) and who failed medical management by Dermatology were referred to Infectious Diseases for daily IV ertapenem through a PICC line. Patients were followed up for at least 6 months after completion of therapy with weekly monitoring. Data including demographics, clinical response/adverse effects to ertapenem and any PICC line-related complications were recorded. Response to the treatment was based on clinical improvement in pain score/drainage and Hurley Staging of HS.
Results. Twenty-three patients with severe HS consented to participate with a median age of 40 years (range 23-78 years) and 56% were female. Median treatment duration was 8 weeks (range 6-12). A 100% response rate was observed within 2 weeks of initiation and near complete resolution of active inflammation/drainage and improvement of pain score was observed in all patients at the end of treatment. Durable response was variable after completion of ertapenem (median 4 weeks; range 2-12); all subjects relapsed with varying degree of severity. In three patients who relapsed back to Hurley Stage III, ertapenem was restarted after 3 months with successful response. Adverse events include diarrhea (four patients), Clostridium difficile infection (one patient), and PICC line-related DVT (three patients). Clinical benefit despite ertapenem non-responsive bacteria in pretreatment culture of cutaneous drainage suggests an unproven immune-modulatory activity. Role of gut/skin microbial alteration needs further study.
Conclusion. In selected patients with severe HS, IV ertapenem is highly effective in the control of inflammation and can be useful in combination with local surgery.
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